OS Therapies (NYSEAMERICAN:OSTX) Stock Price Down 2.6% – What’s Next?

Shares of OS Therapies Incorporated (NYSEAMERICAN:OSTX) fell 2.6% during trading on Friday . The stock traded as low as $1.51 and last traded at $1.52. Approximately 333,232 shares changed hands during trading, a decline of 47% from the average session volume of 625,229 shares. The stock had previously closed at $1.56.

Analyst Upgrades and Downgrades

A number of brokerages have commented on OSTX. D. Boral Capital reissued a “buy” rating and issued a $20.00 price objective on shares of OS Therapies in a research note on Thursday, April 30th. Zacks Research upgraded shares of OS Therapies from a “strong sell” rating to a “hold” rating in a research report on Thursday, June 4th. Lake Street Capital lowered their price target on shares of OS Therapies from $14.00 to $13.00 and set a “buy” rating for the company in a report on Tuesday, May 19th. Finally, Roth Capital started coverage on OS Therapies in a research report on Thursday, July 9th. They issued a “buy” rating and a $7.00 price target for the company. Three investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $13.33.

OS Therapies Stock Performance

The company has a fifty day moving average of $1.73 and a two-hundred day moving average of $1.56. The company has a market cap of $69.22 million, a PE ratio of -1.41 and a beta of -0.83.

OS Therapies (NYSEAMERICAN:OSTX) last issued its quarterly earnings results on Monday, May 18th. The company reported ($0.27) earnings per share (EPS) for the quarter. On average, equities analysts forecast that OS Therapies Incorporated will post -0.94 EPS for the current year.

Institutional Investors Weigh In On OS Therapies

Several institutional investors have recently made changes to their positions in the company. Millennium Management LLC bought a new position in OS Therapies during the 3rd quarter valued at about $183,000. Two Sigma Investments LP bought a new stake in OS Therapies in the third quarter worth about $169,000. Geode Capital Management LLC lifted its stake in OS Therapies by 31.1% in the fourth quarter. Geode Capital Management LLC now owns 246,038 shares of the company’s stock worth $344,000 after purchasing an additional 58,350 shares during the last quarter. Virtu Financial LLC boosted its position in shares of OS Therapies by 252.0% during the third quarter. Virtu Financial LLC now owns 75,801 shares of the company’s stock valued at $149,000 after buying an additional 54,269 shares during the period. Finally, XTX Topco Ltd purchased a new position in shares of OS Therapies during the second quarter valued at approximately $63,000.

About OS Therapies

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Rockville, Maryland.